Bictegravir

Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is a drug of the integrase inhibitor class that was copied from Dolutegravir by scientists at Gilead Sciences (Gilead lost a patent case on this against ViiV); in vitro and clinical results were presented by Gilead in the summer of 2016.[3] In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection[4] and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.[5]

Bictegravir
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
FormulaC21H18F3N3O5
Molar mass449.386 g·mol−1
3D model (JSmol)

References

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.